Nonischemic Myocardial Disease with Clinical Manifestations (Ischemic Cardiomyopathy Already Excluded)

Variant: 1 Suspected hypertrophic cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.

Procedure	Appropriateness Category	Relative Radiation Level
US echocardiography transthoracic resting	Usually Appropriate	O
MRI heart function and morphology without and with IV contrast	Usually Appropriate	O
MRI heart function and morphology without IV contrast	Usually Appropriate	O
US echocardiography transthoracic stress	May Be Appropriate	O
CT heart function and morphology with IV contrast	May Be Appropriate	☢☢☢☢
US echocardiography transesophageal	Usually Not Appropriate	O
Arteriography coronary	Usually Not Appropriate	☢☢☢
Arteriography coronary with ventriculography	Usually Not Appropriate	☢☢☢
MRI chest without and with IV contrast	Usually Not Appropriate	O
MRI chest without IV contrast	Usually Not Appropriate	O
MRI heart with function and inotropic stress without and with IV contrast	Usually Not Appropriate	O
MRI heart with function and inotropic stress without IV contrast	Usually Not Appropriate	O
MRI heart with function and vasodilator stress perfusion without and with IV contrast	Usually Not Appropriate	O
CT chest with IV contrast	Usually Not Appropriate	☢☢☢
CT chest without and with IV contrast	Usually Not Appropriate	☢☢☢
CT chest without IV contrast	Usually Not Appropriate	☢☢☢
CT coronary calcium	Usually Not Appropriate	☢☢☢
CTA coronary arteries with IV contrast	Usually Not Appropriate	☢☢☢
FDG-PET/CT heart	Usually Not Appropriate	☢☢☢☢

Variant: 2 Suspected restrictive cardiomyopathy or infiltrative disease. Ischemic cardiomyopathy already excluded. Initial imaging.

Procedure	Appropriateness Category	Relative Radiation Level
US echocardiography transthoracic resting	Usually Appropriate	O
MRI heart function and morphology without and with IV contrast	Usually Appropriate	O
MRI heart function and morphology without IV contrast	May Be Appropriate	O
CT heart function and morphology with IV contrast	May Be Appropriate	☢☢☢☢
FDG-PET/CT heart	May Be Appropriate	☢☢☢☢
US echocardiography transesophageal	Usually Not Appropriate	O
US echocardiography transthoracic stress	Usually Not Appropriate	O
Arteriography coronary	Usually Not Appropriate	☢☢☢
Arteriography coronary with ventriculography	Usually Not Appropriate	☢☢☢
MRI chest without and with IV contrast	Usually Not Appropriate	O
MRI chest without IV contrast	Usually Not Appropriate	O
MRI heart with function and inotropic stress without and with IV contrast	Usually Not Appropriate	O
MRI heart with function and inotropic stress without IV contrast	Usually Not Appropriate	O
MRI heart with function and vasodilator stress perfusion without and with IV contrast	Usually Not Appropriate	O
CT chest with IV contrast	Usually Not Appropriate	☢☢☢
CT chest without and with IV contrast	Usually Not Appropriate	☢☢☢
CT chest without IV contrast	Usually Not Appropriate	☢☢☢
CT coronary calcium	Usually Not Appropriate	☢☢☢
CTA coronary arteries with IV contrast	Usually Not Appropriate	☢☢☢

Variant: 3 Suspected nonischemic dilated and unclassified cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.

Procedure	Appropriateness Category	Relative Radiation Level
US echocardiography transthoracic resting	Usually Appropriate	O
MRI heart function and morphology without and with IV contrast	Usually Appropriate	O
MRI heart function and morphology without IV contrast	Usually Appropriate	O
CT heart function and morphology with IV contrast	May Be Appropriate	☢☢☢☢
US echocardiography transesophageal	Usually Not Appropriate	O
US echocardiography transthoracic stress	Usually Not Appropriate	O
Arteriography coronary	Usually Not Appropriate	☢☢☢
Arteriography coronary with ventriculography	Usually Not Appropriate	☢☢☢
MRI chest without and with IV contrast	Usually Not Appropriate	O
MRI chest without IV contrast	Usually Not Appropriate	O
MRI heart with function and inotropic stress without and with IV contrast	Usually Not Appropriate	O
MRI heart with function and inotropic stress without IV contrast	Usually Not Appropriate	O
MRI heart with function and vasodilator stress perfusion without and with IV contrast	Usually Not Appropriate	O
CT chest with IV contrast	Usually Not Appropriate	☢☢☢
CT chest without and with IV contrast	Usually Not Appropriate	☢☢☢
CT chest without IV contrast	Usually Not Appropriate	☢☢☢
CT coronary calcium	Usually Not Appropriate	☢☢☢
CTA coronary arteries with IV contrast	Usually Not Appropriate	☢☢☢
FDG-PET/CT heart	Usually Not Appropriate	☢☢☢☢

Variant: 4 Suspected arrhythmogenic cardiomyopathy (arrhythmia of ventricular origin). Ischemic cardiomyopathy already excluded. Initial imaging.

Procedure	Appropriateness Category	Relative Radiation Level
US echocardiography transthoracic resting	Usually Appropriate	O
MRI heart function and morphology without and with IV contrast	Usually Appropriate	O
MRI heart function and morphology without IV contrast	Usually Appropriate	O
CT heart function and morphology with IV contrast	May Be Appropriate	☢☢☢☢
US echocardiography transesophageal	Usually Not Appropriate	O
US echocardiography transthoracic stress	Usually Not Appropriate	O
Arteriography coronary	Usually Not Appropriate	☢☢☢
Arteriography coronary with ventriculography	Usually Not Appropriate	☢☢☢
MRI chest without and with IV contrast	Usually Not Appropriate	O
MRI chest without IV contrast	Usually Not Appropriate	O
MRI heart with function and inotropic stress without and with IV contrast	Usually Not Appropriate	O
MRI heart with function and inotropic stress without IV contrast	Usually Not Appropriate	O
MRI heart with function and vasodilator stress perfusion without and with IV contrast	Usually Not Appropriate	O
CT chest with IV contrast	Usually Not Appropriate	☢☢☢
CT chest without and with IV contrast	Usually Not Appropriate	☢☢☢
CT chest without IV contrast	Usually Not Appropriate	☢☢☢
CT coronary calcium	Usually Not Appropriate	☢☢☢
CTA coronary arteries with IV contrast	Usually Not Appropriate	☢☢☢
FDG-PET/CT heart	Usually Not Appropriate	☢☢☢☢

Variant: 5 Suspected inflammatory cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.

Procedure	Appropriateness Category	Relative Radiation Level
US echocardiography transthoracic resting	Usually Appropriate	O
MRI heart function and morphology without and with IV contrast	Usually Appropriate	O
MRI heart function and morphology without IV contrast	May Be Appropriate	O
CT heart function and morphology with IV contrast	May Be Appropriate	☢☢☢☢
FDG-PET/CT heart	May Be Appropriate	☢☢☢☢
US echocardiography transesophageal	Usually Not Appropriate	O
US echocardiography transthoracic stress	Usually Not Appropriate	O
Arteriography coronary	Usually Not Appropriate	☢☢☢
Arteriography coronary with ventriculography	Usually Not Appropriate	☢☢☢
MRI chest without and with IV contrast	Usually Not Appropriate	O
MRI chest without IV contrast	Usually Not Appropriate	O
MRI heart with function and inotropic stress without and with IV contrast	Usually Not Appropriate	O
MRI heart with function and inotropic stress without IV contrast	Usually Not Appropriate	O
MRI heart with function and vasodilator stress perfusion without and with IV contrast	Usually Not Appropriate	O
CT chest with IV contrast	Usually Not Appropriate	☢☢☢
CT chest without and with IV contrast	Usually Not Appropriate	☢☢☢
CT chest without IV contrast	Usually Not Appropriate	☢☢☢
CT coronary calcium	Usually Not Appropriate	☢☢☢
CTA coronary arteries with IV contrast	Usually Not Appropriate	☢☢☢

Panel Members

Summary of Literature Review

Introduction/Background

Special Imaging Considerations

Initial Imaging Definition

Initial imaging is defined as imaging at the beginning of the care episode for the medical condition defined by the variant. More than one procedure can be considered usually appropriate in the initial imaging evaluation when:

There are procedures that are equivalent alternatives (i.e., only one procedure will be ordered to provide the clinical information to effectively manage the patient’s care)

There are complementary procedures (i.e., more than one procedure is ordered as a set or simultaneously wherein each procedure provides unique clinical information to effectively manage the patient’s care).

Discussion of Procedures by Variant

Variant 1: Suspected hypertrophic cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.

Variant 1: Suspected hypertrophic cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
A. Arteriography Coronary

Variant 1: Suspected hypertrophic cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
B. Arteriography Coronary with Ventriculography

Variant 1: Suspected hypertrophic cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
C. CT Chest

Variant 1: Suspected hypertrophic cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
D. CT Coronary Calcium

Variant 1: Suspected hypertrophic cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
E. CT Heart Function and Morphology

Variant 1: Suspected hypertrophic cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
F. CTA Coronary

Variant 1: Suspected hypertrophic cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
G. FDG-PET/CT Heart

Variant 1: Suspected hypertrophic cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
H. MRI Chest

Variant 1: Suspected hypertrophic cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
I. MRI Heart Function and Morphology

Variant 1: Suspected hypertrophic cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
J. MRI Heart Inotropic Stress

Variant 1: Suspected hypertrophic cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
K. MRI Heart Vasodilator Stress

Variant 1: Suspected hypertrophic cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
L. Echocardiography Transesophageal

Variant 1: Suspected hypertrophic cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
M. Echocardiography Transthoracic Resting

Variant 1: Suspected hypertrophic cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
N. Echocardiography Transthoracic Stress

Variant 2: Suspected restrictive cardiomyopathy or infiltrative disease. Ischemic cardiomyopathy already excluded. Initial imaging.

Variant 2: Suspected restrictive cardiomyopathy or infiltrative disease. Ischemic cardiomyopathy already excluded. Initial imaging.
A. Arteriography Coronary

Variant 2: Suspected restrictive cardiomyopathy or infiltrative disease. Ischemic cardiomyopathy already excluded. Initial imaging.
B. Arteriography Coronary with Ventriculography

Variant 2: Suspected restrictive cardiomyopathy or infiltrative disease. Ischemic cardiomyopathy already excluded. Initial imaging.
C. CT Chest

Variant 2: Suspected restrictive cardiomyopathy or infiltrative disease. Ischemic cardiomyopathy already excluded. Initial imaging.
D. CT Coronary Calcium

Variant 2: Suspected restrictive cardiomyopathy or infiltrative disease. Ischemic cardiomyopathy already excluded. Initial imaging.
E. CT Heart Function and Morphology

Variant 2: Suspected restrictive cardiomyopathy or infiltrative disease. Ischemic cardiomyopathy already excluded. Initial imaging.
F. CTA Coronary

Variant 2: Suspected restrictive cardiomyopathy or infiltrative disease. Ischemic cardiomyopathy already excluded. Initial imaging.
G. Nuclear Medicine

Variant 2: Suspected restrictive cardiomyopathy or infiltrative disease. Ischemic cardiomyopathy already excluded. Initial imaging.
H. FDG-PET/CT Heart

Variant 2: Suspected restrictive cardiomyopathy or infiltrative disease. Ischemic cardiomyopathy already excluded. Initial imaging.
I. MRI Chest

Variant 2: Suspected restrictive cardiomyopathy or infiltrative disease. Ischemic cardiomyopathy already excluded. Initial imaging.
J. MRI Heart Function and Morphology

Variant 2: Suspected restrictive cardiomyopathy or infiltrative disease. Ischemic cardiomyopathy already excluded. Initial imaging.
K. MRI Heart Inotropic Stress

Variant 2: Suspected restrictive cardiomyopathy or infiltrative disease. Ischemic cardiomyopathy already excluded. Initial imaging.
L. MRI Heart Vasodilator Stress

Variant 2: Suspected restrictive cardiomyopathy or infiltrative disease. Ischemic cardiomyopathy already excluded. Initial imaging.
M. Echocardiography Transesophageal

Variant 2: Suspected restrictive cardiomyopathy or infiltrative disease. Ischemic cardiomyopathy already excluded. Initial imaging.
N. Echocardiography Transthoracic Resting

Variant 2: Suspected restrictive cardiomyopathy or infiltrative disease. Ischemic cardiomyopathy already excluded. Initial imaging.
O. Echocardiography Transthoracic Stress

Variant 3: Suspected nonischemic dilated and unclassified cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.

Variant 3: Suspected nonischemic dilated and unclassified cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
A. Arteriography Coronary

Variant 3: Suspected nonischemic dilated and unclassified cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
B. Arteriography Coronary with Ventriculography

Variant 3: Suspected nonischemic dilated and unclassified cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
C. CT Chest

Variant 3: Suspected nonischemic dilated and unclassified cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
D. CT Coronary Calcium

Variant 3: Suspected nonischemic dilated and unclassified cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
E. CT Heart Function and Morphology

Variant 3: Suspected nonischemic dilated and unclassified cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
F. CTA Coronary

Variant 3: Suspected nonischemic dilated and unclassified cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
G. Nuclear Medicine

Variant 3: Suspected nonischemic dilated and unclassified cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
H. FDG-PET/CT Heart

Variant 3: Suspected nonischemic dilated and unclassified cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
I. MRI Chest

Variant 3: Suspected nonischemic dilated and unclassified cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
J. MRI Heart Function and Morphology

Variant 3: Suspected nonischemic dilated and unclassified cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
K. MRI Heart Inotropic Stress

Variant 3: Suspected nonischemic dilated and unclassified cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
L. MRI Heart Vasodilator Stress

Variant 3: Suspected nonischemic dilated and unclassified cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
M. Echocardiography Transesophageal

Variant 3: Suspected nonischemic dilated and unclassified cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
N. Echocardiography Transthoracic Resting

Variant 3: Suspected nonischemic dilated and unclassified cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
O. Echocardiography Transthoracic Stress

Variant 4: Suspected arrhythmogenic cardiomyopathy (arrhythmia of ventricular origin). Ischemic cardiomyopathy already excluded. Initial imaging.

Variant 4: Suspected arrhythmogenic cardiomyopathy (arrhythmia of ventricular origin). Ischemic cardiomyopathy already excluded. Initial imaging.
A. Arteriography Coronary

Variant 4: Suspected arrhythmogenic cardiomyopathy (arrhythmia of ventricular origin). Ischemic cardiomyopathy already excluded. Initial imaging.
B. Arteriography Coronary with Ventriculography

Variant 4: Suspected arrhythmogenic cardiomyopathy (arrhythmia of ventricular origin). Ischemic cardiomyopathy already excluded. Initial imaging.
C. CT Chest

Variant 4: Suspected arrhythmogenic cardiomyopathy (arrhythmia of ventricular origin). Ischemic cardiomyopathy already excluded. Initial imaging.
D. CT Coronary Calcium

Variant 4: Suspected arrhythmogenic cardiomyopathy (arrhythmia of ventricular origin). Ischemic cardiomyopathy already excluded. Initial imaging.
E. CT Heart Function and Morphology

Variant 4: Suspected arrhythmogenic cardiomyopathy (arrhythmia of ventricular origin). Ischemic cardiomyopathy already excluded. Initial imaging.
F. CTA Coronary

Variant 4: Suspected arrhythmogenic cardiomyopathy (arrhythmia of ventricular origin). Ischemic cardiomyopathy already excluded. Initial imaging.
G. FDG-PET/CT Heart

Variant 4: Suspected arrhythmogenic cardiomyopathy (arrhythmia of ventricular origin). Ischemic cardiomyopathy already excluded. Initial imaging.
H. MRI Chest

Variant 4: Suspected arrhythmogenic cardiomyopathy (arrhythmia of ventricular origin). Ischemic cardiomyopathy already excluded. Initial imaging.
I. MRI Heart Function and Morphology

Variant 4: Suspected arrhythmogenic cardiomyopathy (arrhythmia of ventricular origin). Ischemic cardiomyopathy already excluded. Initial imaging.
J. MRI Heart Inotropic Stress

Variant 4: Suspected arrhythmogenic cardiomyopathy (arrhythmia of ventricular origin). Ischemic cardiomyopathy already excluded. Initial imaging.
K. MRI Heart Vasodilator Stress

Variant 4: Suspected arrhythmogenic cardiomyopathy (arrhythmia of ventricular origin). Ischemic cardiomyopathy already excluded. Initial imaging.
L. Echocardiography Transesophageal

Variant 4: Suspected arrhythmogenic cardiomyopathy (arrhythmia of ventricular origin). Ischemic cardiomyopathy already excluded. Initial imaging.
M. Echocardiography Transthoracic Resting

Variant 4: Suspected arrhythmogenic cardiomyopathy (arrhythmia of ventricular origin). Ischemic cardiomyopathy already excluded. Initial imaging.
N. Echocardiography Transthoracic Stress

Variant 5: Suspected inflammatory cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.

Variant 5: Suspected inflammatory cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
A. Arteriography Coronary

Variant 5: Suspected inflammatory cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
B. Arteriography Coronary with Ventriculography

Variant 5: Suspected inflammatory cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
C. CT Chest

Variant 5: Suspected inflammatory cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
D. CT Coronary Calcium

Variant 5: Suspected inflammatory cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
E. CT Heart Function and Morphology

Variant 5: Suspected inflammatory cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
F. CTA Coronary

Variant 5: Suspected inflammatory cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
G. FDG-PET/CT Heart

Variant 5: Suspected inflammatory cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
H. MRI Chest

Variant 5: Suspected inflammatory cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
I. MRI Heart Function and Morphology

Variant 5: Suspected inflammatory cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
J. MRI Heart Inotropic Stress

Variant 5: Suspected inflammatory cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
K. MRI Heart Vasodilator Stress

Variant 5: Suspected inflammatory cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
L. Echocardiography Transesophageal

Variant 5: Suspected inflammatory cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
M. Echocardiography Transthoracic Resting

Variant 5: Suspected inflammatory cardiomyopathy. Ischemic cardiomyopathy already excluded. Initial imaging.
N. Echocardiography Transthoracic Stress

Summary of Recommendations

Supporting Documents

The evidence table, literature search, and appendix for this topic are available at https://acsearch.acr.org/list. The appendix includes the strength of evidence assessment and the final rating round tabulations for each recommendation.

For additional information on the Appropriateness Criteria methodology and other supporting documents, please go to the ACR website at https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Appropriateness-Criteria.

Appropriateness Category Names and Definitions

Appropriateness Category Name	Appropriateness Rating	Appropriateness Category Definition
Usually Appropriate	7, 8, or 9	The imaging procedure or treatment is indicated in the specified clinical scenarios at a favorable risk-benefit ratio for patients.
May Be Appropriate	4, 5, or 6	The imaging procedure or treatment may be indicated in the specified clinical scenarios as an alternative to imaging procedures or treatments with a more favorable risk-benefit ratio, or the risk-benefit ratio for patients is equivocal.
May Be Appropriate (Disagreement)	5	The individual ratings are too dispersed from the panel median. The different label provides transparency regarding the panel’s recommendation. “May be appropriate” is the rating category and a rating of 5 is assigned.
Usually Not Appropriate	1, 2, or 3	The imaging procedure or treatment is unlikely to be indicated in the specified clinical scenarios, or the risk-benefit ratio for patients is likely to be unfavorable.

Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, because of both organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared with those specified for adults (see Table below). Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria^® Radiation Dose Assessment Introduction document.

Relative Radiation Level Designations
Relative Radiation Level*	Adult Effective Dose Estimate Range	Pediatric Effective Dose Estimate Range
O	0 mSv	0 mSv
☢	<0.1 mSv	<0.03 mSv
☢☢	0.1-1 mSv	0.03-0.3 mSv
☢☢☢	1-10 mSv	0.3-3 mSv
☢☢☢☢	10-30 mSv	3-10 mSv
☢☢☢☢☢	30-100 mSv	10-30 mSv
*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (e.g., region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as “Varies.”

References

1.	Bluemke DA. MRI of nonischemic cardiomyopathy. AJR. 2010; 195(4):935-940.
2.	Rajiah P, Raza S, Saboo SS, Ghoshhajra B, Abbara S. Update on the Role of Cardiac Magnetic Resonance in Acquired Nonischemic Cardiomyopathies. [Review]. Journal of Thoracic Imaging. 31(6):348-366, 2016 Nov.
3.	Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 29(2):270-6, 2008 Jan.
4.	Arbustini E, Narula N, Tavazzi L, et al. The MOGE(S) classification of cardiomyopathy for clinicians. [Review][Erratum appears in J Am Coll Cardiol. 2014 Sep 16;64(11):1186 Note: Bonow, Robert D [Corrected to Bonow, Robert O]]. Journal of the American College of Cardiology. 64(3):304-18, 2014 Jul 22.
5.	McKenna WJ, Maron BJ, Thiene G. Classification, Epidemiology, and Global Burden of Cardiomyopathies. [Review]. Circulation Research. 121(7):722-730, 2017 Sep 15.
6.	Follath F. Nonischemic heart failure: epidemiology, pathophysiology, and progression of disease. J Cardiovasc Pharmacol. 1999; 33 Suppl 3:S31-35.
7.	White RD, Kirsch J, Bolen MA, et al. ACR Appropriateness Criteria® Suspected New-Onset and Known Nonacute Heart Failure. J Am Coll Radiol 2018;15:S418-S31.
8.	Expert Panel on Cardiac Imaging:, Vogel-Claussen J, Elshafee ASM, et al. ACR Appropriateness Criteria R Dyspnea-Suspected Cardiac Origin. [Review]. J. Am. Coll. Radiol.. 14(5S):S127-S137, 2017 May.
9.	Ardehali H, Qasim A, Cappola T, et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J. 147(5):919-23, 2004 May.
10.	American College of Radiology. ACR–NASCI–SIR–SPR Practice Parameter for the Performance and Interpretation of Body Computed Tomography Angiography (CTA). Available at: https://gravitas.acr.org/PPTS/GetDocumentView?docId=164+&releaseId=2.
11.	Chan J, Shiino K, Obonyo NG, et al. Left Ventricular Global Strain Analysis by Two-Dimensional Speckle-Tracking Echocardiography: The Learning Curve. J Am Soc Echocardiogr. 30(11):1081-1090, 2017 Nov.
12.	Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 29(4):277-314, 2016 Apr.
13.	Porter TR, Mulvagh SL, Abdelmoneim SS, et al. Clinical Applications of Ultrasonic Enhancing Agents in Echocardiography: 2018 American Society of Echocardiography Guidelines Update. J Am Soc Echocardiogr. 31(3):241-274, 2018 03.
14.	Harinstein ME, Soman P. Radionuclide Imaging Applications in Cardiomyopathies and Heart Failure. [Review]. Current Cardiology Reports. 18(3):23, 2016 Mar.
15.	Kalisz K, Rajiah P. Computed tomography of cardiomyopathies. [Review]. Cardiovascular Diagnosis & Therapy. 7(5):539-556, 2017 Oct.
16.	Asferg C, Usinger L, Kristensen TS, Abdulla J. Accuracy of multi-slice computed tomography for measurement of left ventricular ejection fraction compared with cardiac magnetic resonance imaging and two-dimensional transthoracic echocardiography: a systematic review and meta-analysis. [Review]. Eur J Radiol. 81(5):e757-62, 2012 May.
17.	Greupner J, Zimmermann E, Grohmann A, et al. Head-to-head comparison of left ventricular function assessment with 64-row computed tomography, biplane left cineventriculography, and both 2- and 3-dimensional transthoracic echocardiography: comparison with magnetic resonance imaging as the reference standard.[Erratum appears in J Am Coll Cardiol. 2012 Jul 31;60(5):481 Note: Althoff, Till [corrected to Althoff, Till F]]. Journal of the American College of Cardiology. 59(21):1897-907, 2012 May 22.
18.	Lee HJ, Im DJ, Youn JC, et al. Myocardial Extracellular Volume Fraction with Dual-Energy Equilibrium Contrast-enhanced Cardiac CT in Nonischemic Cardiomyopathy: A Prospective Comparison with Cardiac MR Imaging. Radiology. 280(1):49-57, 2016 Jul.
19.	Buss SJ, Schulz F, Mereles D, et al. Quantitative analysis of left ventricular strain using cardiac computed tomography. European Journal of Radiology. 83(3):e123-30, 2014 Mar.
20.	Boogers MJ, van Werkhoven JM, Schuijf JD, et al. Feasibility of diastolic function assessment with cardiac CT: feasibility study in comparison with tissue Doppler imaging. Jacc: Cardiovascular Imaging. 4(3):246-56, 2011 Mar.
21.	Captur G, Manisty C, Moon JC. Cardiac MRI evaluation of myocardial disease. [Review]. Heart. 102(18):1429-35, 2016 09 15.
22.	O'Donnell DH, Abbara S, Chaithiraphan V, et al. Cardiac MR imaging of nonischemic cardiomyopathies: imaging protocols and spectra of appearances.[Erratum appears in Radiology. 2015 Oct;277(1):308; PMID: 26402503]. Radiology. 262(2):403-22, 2012 Feb.
23.	Messroghli DR, Moon JC, Ferreira VM, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI).[Erratum appears in J Cardiovasc Magn Reson. 2018 Feb 7;20(1):9; PMID: 29415744]. Journal of Cardiovascular Magnetic Resonance. 19(1):75, 2017 Oct 09.
24.	Moon JC, Messroghli DR, Kellman P, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. [Review]. Journal of Cardiovascular Magnetic Resonance. 15:92, 2013 Oct 14.
25.	Indik JH, Gimbel JR, Abe H, et al. 2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices. [Review]. Heart Rhythm. 14(7):e97-e153, 2017 07.
26.	Nazarian S, Hansford R, Roguin A, et al. A prospective evaluation of a protocol for magnetic resonance imaging of patients with implanted cardiac devices. Ann Intern Med. 2011; 155(7):415-424.
27.	Russo RJ, Costa HS, Silva PD, et al. Assessing the Risks Associated with MRI in Patients with a Pacemaker or Defibrillator. N Engl J Med. 376(8):755-764, 2017 02 23.
28.	Williamson BD, Gohn DC, Ramza BM, et al. Real-World Evaluation of Magnetic Resonance Imaging in Patients With a Magnetic Resonance Imaging Conditional Pacemaker System: Results of 4-Year Prospective Follow-Up in 2,629 Patients. JACC Clin Electrophysiol. 3(11):1231-1239, 2017 11.
29.	Rashid S, Rapacchi S, Vaseghi M, et al. Improved late gadolinium enhancement MR imaging for patients with implanted cardiac devices. Radiology. 270(1):269-74, 2014 Jan.
30.	Stevens SM, Tung R, Rashid S, et al. Device artifact reduction for magnetic resonance imaging of patients with implantable cardioverter-defibrillators and ventricular tachycardia: late gadolinium enhancement correlation with electroanatomic mapping. Heart Rhythm. 11(2):289-98, 2014 Feb.
31.	Hurrell DG, Nishimura RA, Higano ST, et al. Value of dynamic respiratory changes in left and right ventricular pressures for the diagnosis of constrictive pericarditis. Circulation. 93(11):2007-13, 1996 Jun 01.
32.	Baxi AJ, Restrepo CS, Vargas D, Marmol-Velez A, Ocazionez D, Murillo H. Hypertrophic Cardiomyopathy from A to Z: Genetics, Pathophysiology, Imaging, and Management. [Review]. Radiographics. 36(2):335-54, 2016 Mar-Apr.
33.	Marian AJ, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. [Review]. Circulation Research. 121(7):749-770, 2017 Sep 15.
34.	Patel P, Dhillon A, Popovic ZB, et al. Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy Patients Without Severe Septal Hypertrophy: Implications of Mitral Valve and Papillary Muscle Abnormalities Assessed Using Cardiac Magnetic Resonance and Echocardiography. Circulation. Cardiovascular imaging. 8(7):e003132, 2015 Jul.
35.	De Cobelli F, Esposito A, Belloni E, et al. Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy. AJR. American Journal of Roentgenology. 192(3):W97-102, 2009 Mar.
36.	Langer C, Lutz M, Eden M, et al. Hypertrophic cardiomyopathy in cardiac CT: a validation study on the detection of intramyocardial fibrosis in consecutive patients. The International Journal of Cardiovascular Imaging. 30(3):659-67, 2014 Mar.
37.	Zhao L, Ma X, Feuchtner GM, Zhang C, Fan Z. Quantification of myocardial delayed enhancement and wall thickness in hypertrophic cardiomyopathy: multidetector computed tomography versus magnetic resonance imaging. European Journal of Radiology. 83(10):1778-85, 2014 Oct.
38.	Zhao L, Ma X, Delano MC, et al. Assessment of myocardial fibrosis and coronary arteries in hypertrophic cardiomyopathy using combined arterial and delayed enhanced CT: comparison with MR and coronary angiography. European Radiology. 23(4):1034-43, 2013 Apr.
39.	Maron MS.. The role of cardiovascular magnetic resonance in sudden death risk stratification in hypertrophic cardiomyopathy. [Review]. Cardiac electrophysiology clinics. 7(2):187-93, 2015 Jun.
40.	Maron MS.. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. [Review]. Journal of Cardiovascular Magnetic Resonance. 14:13, 2012 Feb 01.
41.	Puntmann VO, Jahnke C, Gebker R, et al. Usefulness of magnetic resonance imaging to distinguish hypertensive and hypertrophic cardiomyopathy. Am J Cardiol. 2010; 106(7):1016-1022.
42.	Puntmann VO, Voigt T, Chen Z, et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. Jacc: Cardiovascular Imaging. 6(4):475-84, 2013 Apr.
43.	Kwon DH, Setser RM, Thamilarasan M, et al. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Heart. 94(10):1295-301, 2008 Oct.
44.	Pica S, Sado DM, Maestrini V, et al. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance. 16:99, 2014 Dec 05.
45.	Vijapurapu R, Nordin S, Baig S, et al. Global longitudinal strain, myocardial storage and hypertrophy in Fabry disease. Heart. 105(6):470-476, 2019 03.
46.	Dara BS, Rusconi PG, Fishman JE. Danon disease: characteristic late gadolinium enhancement pattern on cardiac magnetic resonance imaging. Cardiology in the Young. 21(6):707-9, 2011 Dec.
47.	Etesami M, Gilkeson RC, Rajiah P. Utility of late gadolinium enhancement in pediatric cardiac MRI. [Review]. Pediatric Radiology. 46(8):1096-113, 2016 Jul.
48.	Hernandez LE.. Myocardial stress perfusion magnetic resonance in children with hypertrophic cardiomyopathy. Cardiol Young. 28(5):702-708, 2018 May.
49.	Ismail TF, Hsu LY, Greve AM, et al. Coronary microvascular ischemia in hypertrophic cardiomyopathy - a pixel-wise quantitative cardiovascular magnetic resonance perfusion study. J Cardiovasc Magn Reson. 16:49, 2014 Aug 12.
50.	Nagueh SF, Bierig SM, Budoff MJ, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 24(5):473-98, 2011 May.
51.	Authors/Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 35(39):2733-79, 2014 Oct 14.
52.	Seward JB, Casaclang-Verzosa G. Infiltrative cardiovascular diseases: cardiomyopathies that look alike. [Review] [84 refs]. Journal of the American College of Cardiology. 55(17):1769-79, 2010 Apr 27.
53.	Doughan AR, Williams BR. Cardiac sarcoidosis. [Review] [20 refs]. Heart. 92(2):282-8, 2006 Feb.
54.	Ohira H, Tsujino I, Ishimaru S, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. European Journal of Nuclear Medicine & Molecular Imaging. 35(5):933-41, 2008 May.
55.	Dubrey SW, Sharma R, Underwood R, Mittal T. Cardiac sarcoidosis: diagnosis and management. [Review]. Postgraduate Medical Journal. 91(1077):384-94, 2015 Jul.
56.	Salemi VM, Rochitte CE, Shiozaki AA, et al. Late gadolinium enhancement magnetic resonance imaging in the diagnosis and prognosis of endomyocardial fibrosis patients. Circulation. Cardiovascular imaging. 4(3):304-11, 2011 May.
57.	Deux JF, Mihalache CI, Legou F, et al. Noninvasive detection of cardiac amyloidosis using delayed enhanced MDCT: a pilot study. European Radiology. 25(8):2291-7, 2015 Aug.
58.	Treibel TA, Bandula S, Fontana M, et al. Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. Journal of cardiovascular computed tomography. 9(6):585-92, 2015 Nov-Dec.
59.	Aikawa T, Oyama-Manabe N, Naya M, et al. Delayed contrast-enhanced computed tomography in patients with known or suspected cardiac sarcoidosis: A feasibility study. European Radiology. 27(10):4054-4063, 2017 Oct.
60.	Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. [Review]. Journal of Nuclear Medicine. 53(2):241-8, 2012 Feb.
61.	Hanneman K, Kadoch M, Guo HH, et al. Initial Experience With Simultaneous 18F-FDG PET/MRI in the Evaluation of Cardiac Sarcoidosis and Myocarditis. Clinical Nuclear Medicine. 42(7):e328-e334, 2017 Jul.
62.	Wassmuth R, Abdel-Aty H, Bohl S, Schulz-Menger J. Prognostic impact of T2-weighted CMR imaging for cardiac amyloidosis. Eur Radiol. 21(8):1643-50, 2011 Aug.
63.	Zhao L, Tian Z, Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis. [Review]. BMC Cardiovascular Disorders. 16:129, 2016 06 07.
64.	Dungu JN, Valencia O, Pinney JH, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. Jacc: Cardiovascular Imaging. 7(2):133-42, 2014 Feb.
65.	Karamitsos TD, Piechnik SK, Banypersad SM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. Jacc: Cardiovascular Imaging. 6(4):488-97, 2013 Apr.
66.	Fontana M, Pica S, Reant P, et al. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 132(16):1570-9, 2015 Oct 20.
67.	Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. Journal of Cardiovascular Magnetic Resonance. 10:54, 2008 Nov 25.
68.	Freeman AM, Curran-Everett D, Weinberger HD, et al. Predictors of cardiac sarcoidosis using commonly available cardiac studies. American Journal of Cardiology. 112(2):280-5, 2013 Jul 15.
69.	Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005; 45(10):1683-1690.
70.	Giesbrandt KJ, Bolan CW, Shapiro BP, Edwards WD, Mergo PJ. Diffuse diseases of the myocardium: MRI-pathologic review of cardiomyopathies with dilatation. [Review]. AJR. American Journal of Roentgenology. 200(3):W274-82, 2013 Mar.
71.	Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. Jacc: Cardiovascular Imaging. 6(4):501-11, 2013 Apr.
72.	Ise T, Hasegawa T, Morita Y, et al. Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis. Heart. 100(15):1165-72, 2014 Aug.
73.	Puntmann VO, Isted A, Hinojar R, Foote L, Carr-White G, Nagel E. T1 and T2 Mapping in Recognition of Early Cardiac Involvement in Systemic Sarcoidosis. Radiology. 285(1):63-72, 2017 10.
74.	Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001; 22(23):2171-2179.
75.	Sado DM, Maestrini V, Piechnik SK, et al. Noncontrast myocardial T1 mapping using cardiovascular magnetic resonance for iron overload. Journal of Magnetic Resonance Imaging. 41(6):1505-11, 2015 Jun.
76.	Pennell DJ, Udelson JE, Arai AE, et al. Cardiovascular function and treatment in beta-thalassemia major: a consensus statement from the American Heart Association. Circulation. 128(3):281-308, 2013 Jul 16.
77.	Tzelepis GE, Kelekis NL, Plastiras SC, et al. Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis & Rheumatism. 56(11):3827-36, 2007 Nov.
78.	Ntusi NA, Piechnik SK, Francis JM, et al. Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis--a clinical study using myocardial T1-mapping and extracellular volume quantification. Journal of Cardiovascular Magnetic Resonance. 16:21, 2014 Mar 04.
79.	Syed IS, Martinez MW, Feng DL, Glockner JF. Cardiac magnetic resonance imaging of eosinophilic endomyocardial disease. International Journal of Cardiology. 126(3):e50-2, 2008 Jun 06.
80.	Nihoyannopoulos P, Dawson D. Restrictive cardiomyopathies. [Review] [14 refs]. Eur J Echocardiogr. 10(8):iii23-33, 2009 Dec.
81.	Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 98(19):1442-8, 2012 Oct.
82.	Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-327.
83.	Walker CM, Saldana DA, Gladish GW, et al. Cardiac complications of oncologic therapy. [Review]. Radiographics. 33(6):1801-15, 2013 Oct.
84.	Arora NP, Mohamad T, Mahajan N, et al. Cardiac magnetic resonance imaging in peripartum cardiomyopathy. American Journal of the Medical Sciences. 347(2):112-7, 2014 Feb.
85.	Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. [Review]. European Journal of Heart Failure. 12(8):767-78, 2010 Aug.
86.	Grothoff M, Pachowsky M, Hoffmann J, et al. Value of cardiovascular MR in diagnosing left ventricular non-compaction cardiomyopathy and in discriminating between other cardiomyopathies. European Radiology. 22(12):2699-709, 2012 Dec.
87.	Abbas A, Sonnex E, Pereira RS, Coulden RA. Cardiac magnetic resonance assessment of takotsubo cardiomyopathy. [Review]. Clinical Radiology. 71(1):e110-9, 2016 Jan.
88.	Kurisu S, Inoue I, Kawagoe T, et al. Prevalence of incidental coronary artery disease in tako-tsubo cardiomyopathy. Coronary Artery Disease. 20(3):214-8, 2009 May.
89.	Ghadri JR, Wittstein IS, Prasad A, et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. European Heart Journal. 39(22):2032-2046, 2018 Jun 07.
90.	Redfors B, Ramunddal T, Shao Y, Omerovic E. Takotsubo triggered by acute myocardial infarction: a common but overlooked syndrome?. Journal of Geriatric Cardiology. 11(2):171-3, 2014 Jun.
91.	Andreini D, Pontone G, Pepi M, et al. Diagnostic accuracy of multidetector computed tomography coronary angiography in patients with dilated cardiomyopathy. Journal of the American College of Cardiology. 49(20):2044-50, 2007 May 22.
92.	Sidhu MS, Uthamalingam S, Ahmed W, et al. Defining left ventricular noncompaction using cardiac computed tomography. Journal of Thoracic Imaging. 29(1):60-6, 2014 Jan.
93.	Hussain J, Ghandforoush A, Virk Z, Cherukuri M. Viability assessment by multidetector computed tomography in Takotsubo cardiomyopathy. Journal of Thoracic Imaging. 26(1):W7-8, 2011 Feb.
94.	Otalvaro L, Zambrano JP, Fishman JE. Takotsubo cardiomyopathy: utility of cardiac computed tomography angiography for acute diagnosis. J Thorac Imaging 2011;26:W83-5.
95.	Ghadri JR, Wittstein IS, Prasad A, et al. International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. Eur Heart J. 39(22):2047-2062, 2018 06 07.
96.	Tung R, Bauer B, Schelbert H, et al. Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias: The potential role of occult inflammation in arrhythmogenesis. Heart Rhythm. 12(12):2488-98, 2015 Dec.
97.	McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003 Jul 08;108(1):54-9.
98.	Gulati A, Jabbour A, Ismail TF, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy.[Erratum appears in JAMA. 2013 Jul 3;310(1):99]. JAMA. 309(9):896-908, 2013 Mar 06.
99.	Puntmann VO, Carr-White G, Jabbour A, et al. T1-Mapping and Outcome in Nonischemic Cardiomyopathy: All-Cause Mortality and Heart Failure. Jacc: Cardiovascular Imaging. 9(1):40-50, 2016 Jan.
100.	Lopez-Fernandez T, Thavendiranathan P. Emerging Cardiac Imaging Modalities for the Early Detection of Cardiotoxicity Due to Anticancer Therapies. [Review]. Rev Esp Cardiol (Engl). 70(6):487-495, 2017 Jun.
101.	Thavendiranathan P, Wintersperger BJ, Flamm SD, Marwick TH. Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. [Review]. Circulation. Cardiovascular imaging. 6(6):1080-91, 2013 Nov.
102.	Ylanen K, Poutanen T, Savikurki-Heikkila P, Rinta-Kiikka I, Eerola A, Vettenranta K. Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer. Journal of the American College of Cardiology. 61(14):1539-47, 2013 Apr 09.
103.	Renz DM, Rottgen R, Habedank D, et al. New insights into peripartum cardiomyopathy using cardiac magnetic resonance imaging. Rofo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. 183(9):834-41, 2011 Sep.
104.	Verhaert D, Richards K, Rafael-Fortney JA, Raman SV. Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations. [Review]. Circulation. Cardiovascular imaging. 4(1):67-76, 2011 Jan.
105.	Tandon A, Villa CR, Hor KN, et al. Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy. Journal of the American Heart Association. 4(4), 2015 Mar 26.
106.	Hagenbuch SC, Gottliebson WM, Wansapura J, et al. Detection of progressive cardiac dysfunction by serial evaluation of circumferential strain in patients with Duchenne muscular dystrophy. American Journal of Cardiology. 105(10):1451-5, 2010 May 15.
107.	Jacquier A, Thuny F, Jop B, et al. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. European Heart Journal. 31(9):1098-104, 2010 May.
108.	Ashrith G, Gupta D, Hanmer J, Weiss RM. Cardiovascular magnetic resonance characterization of left ventricular non-compaction provides independent prognostic information in patients with incident heart failure or suspected cardiomyopathy. Journal of Cardiovascular Magnetic Resonance. 16:64, 2014 Oct 02.
109.	Dodd JD, Holmvang G, Hoffmann U, et al. Quantification of left ventricular noncompaction and trabecular delayed hyperenhancement with cardiac MRI: correlation with clinical severity. AJR. American Journal of Roentgenology. 189(4):974-80, 2007 Oct.
110.	Thuny F, Jacquier A, Jop B, et al. Assessment of left ventricular non-compaction in adults: side-by-side comparison of cardiac magnetic resonance imaging with echocardiography. Archives of cardiovascular diseases. 103(3):150-9, 2010 Mar.
111.	Stacey RB, Andersen MM, St Clair M, Hundley WG, Thohan V. Comparison of systolic and diastolic criteria for isolated LV noncompaction in CMR. Jacc: Cardiovascular Imaging. 6(9):931-40, 2013 Sep.
112.	Kawel N, Nacif M, Arai AE, et al. Trabeculated (noncompacted) and compact myocardium in adults: the multi-ethnic study of atherosclerosis. Circulation. Cardiovascular imaging. 5(3):357-66, 2012 May 01.
113.	Weir-McCall JR, Yeap PM, Papagiorcopulo C, et al. Left Ventricular Noncompaction: Anatomical Phenotype or Distinct Cardiomyopathy?. Journal of the American College of Cardiology. 68(20):2157-2165, 2016 Nov 15.
114.	Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P, et al. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. JAMA. 306(3):277-86, 2011 Jul 20.
115.	Ferreira VM, Piechnik SK, Dall'Armellina E, et al. Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance. 14:42, 2012 Jun 21.
116.	Nakamori S, Matsuoka K, Onishi K, et al. Prevalence and signal characteristics of late gadolinium enhancement on contrast-enhanced magnetic resonance imaging in patients with takotsubo cardiomyopathy. Circulation Journal. 76(4):914-21, 2012.
117.	Naruse Y, Sato A, Kasahara K, et al. The clinical impact of late gadolinium enhancement in Takotsubo cardiomyopathy: serial analysis of cardiovascular magnetic resonance images. Journal of Cardiovascular Magnetic Resonance. 13:67, 2011 Oct 29.
118.	Scally C, Rudd A, Mezincescu A, et al. Persistent Long-Term Structural, Functional, and Metabolic Changes After Stress-Induced (Takotsubo) Cardiomyopathy. Circulation. 137(10):1039-1048, 2018 03 06.
119.	Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. [Review]. Journal of the American College of Cardiology. 63(25 Pt A):2751-68, 2014 Jul 01.
120.	Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. [Review]. European Journal of Heart Failure. 18(9):1096-105, 2016 09.
121.	Zhang X, Yuan L, Qiu L, et al. Incremental value of contrast echocardiography in the diagnosis of left ventricular noncompaction. Fronteras en Medicina. 10(4):499-506, 2016 Dec.
122.	Kalapos A, Domsik P, Forster T, Nemes A. Left ventricular strain reduction is not confined to the noncompacted segments in noncompaction cardiomyopathy-insights from the three-dimensional speckle tracking echocardiographic MAGYAR-path study. Echocardiography. 31(5):638-43, 2014 May.
123.	Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J. 2010;31(7):806-814.
124.	te Riele AS, Tandri H, Bluemke DA. Arrhythmogenic right ventricular cardiomyopathy (ARVC): cardiovascular magnetic resonance update. [Review]. Journal of Cardiovascular Magnetic Resonance. 16:50, 2014 Jul 20.
125.	Huizar JF, Ellenbogen KA, Tan AY, Kaszala K. Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review. [Review]. J Am Coll Cardiol. 73(18):2328-2344, 2019 May 14.
126.	Hasdemir C, Yuksel A, Camli D, et al. Late gadolinium enhancement CMR in patients with tachycardia-induced cardiomyopathy caused by idiopathic ventricular arrhythmias. Pacing & Clinical Electrophysiology. 35(4):465-70, 2012 Apr.
127.	Nakajima T, Kimura F, Kajimoto K, Kasanuki H, Hagiwara N. Utility of ECG-gated MDCT to differentiate patients with ARVC/D from patients with ventricular tachyarrhythmias. J Cardiovasc Comput Tomogr 2013;7:223-33.
128.	Bourfiss M, Vigneault DM, Aliyari Ghasebeh M, et al. Feature tracking CMR reveals abnormal strain in preclinical arrhythmogenic right ventricular dysplasia/ cardiomyopathy: a multisoftware feasibility and clinical implementation study. J Cardiovasc Magn Reson. 19(1):66, 2017 Sep 01.
129.	Vigneault DM, te Riele AS, James CA, et al. Right ventricular strain by MR quantitatively identifies regional dysfunction in patients with arrhythmogenic right ventricular cardiomyopathy. J Magn Reson Imaging. 43(5):1132-9, 2016 May.
130.	Saberniak J, Leren IS, Haland TF, et al. Comparison of patients with early-phase arrhythmogenic right ventricular cardiomyopathy and right ventricular outflow tract ventricular tachycardia. European heart journal cardiovascular Imaging. 18(1):62-69, 2017 Jan.
131.	Piers SR, Tao Q, van Huls van Taxis CF, Schalij MJ, van der Geest RJ, Zeppenfeld K. Contrast-enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonischemic cardiomyopathy: implications for the ablation strategy. Circulation: Arrhythmia and Electrophysiology. 6(5):875-83, 2013 Oct.
132.	Ferreira VM, Piechnik SK, Dall'Armellina E, et al. T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging. Jacc: Cardiovascular Imaging. 6(10):1048-1058, 2013 Oct.
133.	Prasad M, Hermann J, Gabriel SE, et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. [Review]. Nat Rev Cardiol. 12(3):168-76, 2015 Mar.
134.	Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec 2015;90:33-43.
135.	Torreao JA, Ianni BM, Mady C, et al. Myocardial tissue characterization in Chagas' heart disease by cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance. 17:97, 2015 Nov 18.
136.	Dambrin G, Laissy JP, Serfaty JM, Caussin C, Lancelin B, Paul JF. Diagnostic value of ECG-gated multidetector computed tomography in the early phase of suspected acute myocarditis. A preliminary comparative study with cardiac MRI. European Radiology. 17(2):331-8, 2007 Feb.
137.	Patriki D, Gresser E, Manka R, Emmert MY, Luscher TF, Heidecker B. Approximation of the Incidence of Myocarditis by Systematic Screening With Cardiac Magnetic Resonance Imaging. JACC Heart Failure. 6(7):573-579, 2018 07.JACC Heart Fail. 6(7):573-579, 2018 07.
138.	Chu GC, Flewitt JA, Mikami Y, Vermes E, Friedrich MG. Assessment of acute myocarditis by cardiovascular MR: diagnostic performance of shortened protocols. The International Journal of Cardiovascular Imaging. 29(5):1077-83, 2013 Jun.
139.	Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. [Review]. J Am Coll Cardiol. 72(24):3158-3176, 2018 12 18.
140.	Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 2006;114:1581-90.
141.	Berg J, Kottwitz J, Baltensperger N, et al. Cardiac Magnetic Resonance Imaging in Myocarditis Reveals Persistent Disease Activity Despite Normalization of Cardiac Enzymes and Inflammatory Parameters at 3-Month Follow-Up. Circulation: Heart Failure. 10(11), 2017 Nov.
142.	Schumm J, Greulich S, Wagner A, et al. Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis. Journal of Cardiovascular Magnetic Resonance. 16:14, 2014 Jan 26.
143.	Regueiro A, Garcia-Alvarez A, Sitges M, et al. Myocardial involvement in Chagas disease: insights from cardiac magnetic resonance. International Journal of Cardiology. 165(1):107-12, 2013 Apr 30.
144.	Acquatella H, Asch FM, Barbosa MM, et al. Recommendations for Multimodality Cardiac Imaging in Patients with Chagas Disease: A Report from the American Society of Echocardiography in Collaboration With the InterAmerican Association of Echocardiography (ECOSIAC) and the Cardiovascular Imaging Department of the Brazilian Society of Cardiology (DIC-SBC). J Am Soc Echocardiogr. 31(1):3-25, 2018 01.
145.	Gomes VA, Alves GF, Hadlich M, et al. Analysis of Regional Left Ventricular Strain in Patients with Chagas Disease and Normal Left Ventricular Systolic Function. J Am Soc Echocardiogr. 29(7):679-88, 2016 07.
146.	American College of Radiology. ACR Appropriateness Criteria® Radiation Dose Assessment Introduction. Available at: https://edge.sitecorecloud.io/americancoldf5f-acrorgf92a-productioncb02-3650/media/ACR/Files/Clinical/Appropriateness-Criteria/ACR-Appropriateness-Criteria-Radiation-Dose-Assessment-Introduction.pdf.

Disclaimer

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient’s clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient’s condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.